Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2

Louis Firket; Julie Descy; Laurence Seidel; Catherine Bonvoisin; Antoine Bouquegneau; Stéphanie Grosch; François Jouret; Laurent Weekers

doi:10.1111/ajt.16726

Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2

Am J Transplant. 2021 Nov;21(11):3806-3807. doi: 10.1111/ajt.16726. Epub 2021 Jul 10.

Authors

Louis Firket¹, Julie Descy², Laurence Seidel³, Catherine Bonvoisin¹, Antoine Bouquegneau¹, Stéphanie Grosch¹, François Jouret^{1

4}, Laurent Weekers¹

Affiliations

¹ Division of Nephrology, University of Liege Hospital (ULiege CHU), Liege, Belgium.
² Division of Microbiology, University of Liege Hospital (ULiege CHU), Liege, Belgium.
³ Division of Biostatistics, University of Liege Hospital (ULiege CHU), Liege, Belgium.
⁴ Laboratory of Translational Research in Nephrology, University of Liege GIGA Research Center, ULiege, Liege, Belgium.

No abstract available

Keywords: clinical research/practice; immunosuppressant; immunosuppression/immune modulation; infection and infectious agents - viral; infectious disease; kidney transplantation/nephrology; vaccine.

Publication types

Letter
Comment

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Kidney Transplantation* / adverse effects
RNA, Messenger
SARS-CoV-2
Transplant Recipients

Substances

COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine